Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| Insilico Medicine | Cambridge | Series E | $123.0M | 2025-03-13 |
| Albert Invent | Oakland | Series B | $55.0M | 2026-10-13 |
| T-Therapeutics | Cambridge | Series B | $133.0M | 2026-11-05 |
| Avalyn Pharma | Seattle | Series D | $100.0M | 2025-07-22 |
| TraceLink | North Reading | Series D | $93.0M | 2018-08-21 |
| Canary Technologies | San Francisco | Series D | $80.0M | 2025-06-12 |
| Xaira Therapeutics | South San Francisco | Series A | $1.0B | 2024-04-23 |
| Lighthouse | London | Series C | $370.0M | 2024-11-21 |
8 rows of the CSV in 5 of its 18 columns.
- The 75 F-Prime portfolio companies have raised $7.7B in total.
- 4 of them closed their most recent round in the last 12 months, $221.5M combined.
- The largest of those rounds is T-Therapeutics' $133.0M Series B, dated November 2026.
- Eight Roads Ventures is an investor in 25 of them, more than any other fund.
- Software is the most common sector, with 51 companies (68%).
- 27% were founded in 2020 or later; the median founding year is 2015.
- The most common team size is 51 to 100 employees (32% of companies with a recorded size).
- 2 are unicorns, valued at $1 billion or more.
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
30 of 75| Company | What they do | Sector | Location | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| T-Therapeutics | T-Therapeutics develops T cell receptor therapies, spun off from the University of Cambridge. | Biotech | Cambridge, United Kingdom | Series B | $133.0M | 2026-11-05 | $224.6M | F-Prime, Sofinnova Partners, Digitalis Ventures +2 | 51 to 100 | 2022 |
| Albert Invent | Albert Invent builds an AI platform that supports chemistry research and development for scientific and industrial users. | Artificial intelligence | Oakland, United States | Series B | $55.0M | 2026-10-13 | $105.0M | Index Ventures, F-Prime, Homebrew | 101 to 250 | 2022 |
| Immuneel Therapeutics | Immuneel Therapeutics develops cell and gene therapies to treat cancer. | Health care | Bangalore, India | Series B | $10.5M | 2026-06-08 | $37.6M | Eight Roads Ventures, F-Prime, True North | 51 to 100 | 2018 |
| Nocion Therapeutics | Nocion Therapeutics develops pharmaceuticals to treat conditions arising from neurogenic inflammation. | Biotech | Cambridge, United States | Series B | $23.0M | 2026-01-07 | $134.0M | Canaan Partners, F-Prime, OUP (Osage University Partners) +2 | 11 to 50 | 2017 |
| Dispatch | Dispatch helps independent financial advisors build their own firms through strategic investments and technology. | Fintech | Miami, United States | Series A | $18.0M | 2025-09-04 | $32.9M | Great Oaks Venture Capital, F-Prime, Fika Ventures +1 | 11 to 50 | 2022 |
| Avalyn Pharma | Avalyn Pharma develops therapies for idiopathic pulmonary fibrosis and other respiratory diseases. | Biotech | Seattle, United States | Series D | $100.0M | 2025-07-22 | $372.5M | Eight Roads Ventures, F-Prime, Wellington Management +2 | 11 to 50 | 2011 |
| Canary Technologies | Canary Technologies provides a digital guest management platform for hotels covering check-in, messaging, payments, and upsells. | Artificial intelligence | San Francisco, United States | Series D | $80.0M | 2025-06-12 | $177.0M | Y Combinator, Insight Partners, Pioneer Fund +2 | 251 to 500 | 2017 |
| Toku | Toku automates payment collection for companies in Latin America through its payment relationship management platform. | Fintech | Santiago, Chile | Series A | $48.0M | 2025-04-17 | $66.5M | Y Combinator, Pareto Holdings, F-Prime +1 | 101 to 250 | 2020 |
| Insilico Medicine | Insilico Medicine develops an AI platform for drug development targeting cancer and age-related diseases. | Artificial intelligence | Cambridge, United States | Series E | $123.0M | 2025-03-13 | $624.3M | Qiming Venture Partners, F-Prime, Warburg Pincus +1 | 101 to 250 | 2014 |
| 1Money Network Technologies | 1Money Network Technologies operates a payment network that lets users transfer money. | Fintech | Hamilton, Bermuda | Seed | $20.0M | 2025-01-15 | $20.0M | F-Prime, Borderless Capital, Tribe Capital +1 | 11 to 50 | 2024 |
| Rhygaze | Rhygaze develops a gene therapy that targets cone cells to restore vision in blinding diseases. | Biotech | Basel, Switzerland | Series A | $86.0M | 2025-01-10 | $97.3M | Google Ventures, F-Prime, ARCH Venture Partners +2 | 11 to 50 | 2024 |
| Lighthouse Unicorn | Lighthouse provides a commercial platform for the travel and hospitality industry. | Software | London, United Kingdom | Series C | $370.0M | 2024-11-21 | $470.0M | Eight Roads Ventures, F-Prime, Venrex +2 | 501 to 1,000 | 2012 |
| Mozper | Mozper provides a debit card and money app that helps families manage their finances. | Fintech | Mexico City, Mexico | Seed | $979K | 2024-09-30 | Y Combinator, Foundation Capital, F-Prime +2 | 11 to 50 | 2019 | |
| Whatfix | Whatfix provides GenAI-powered in-app guidance, simulated training, and analytics to help users adopt digital tools. | Education | Bangalore, India | Series E | $125.0M | 2024-09-25 | $264.8M | Sequoia Capital, Peak XV Partners, F-Prime +2 | 501 to 1,000 | 2014 |
| Shinobi Therapeutics | Shinobi Therapeutics develops immune-evasive iPS cell therapies for cancer treatment. | Biotech | South San Francisco, United States | Series A | $68.0M | 2024-08-06 | $178.0M | Mitsubishi UFJ Capital, F-Prime, EQT Life Sciences +2 | 11 to 50 | 2023 |
| Odaseva | Odaseva provides data security and management solutions for enterprises running on Salesforce. | Cybersecurity | San Francisco, United States | Series C | $54.0M | 2024-06-27 | $93.0M | Salesforce Ventures, Partech, Eight Roads Ventures +2 | 101 to 250 | 2012 |
| Quantum Circuits | Quantum Circuits is building a full-stack quantum computer based on dual-rail qubits. | Hardware | New Haven, United States | Series B | $60.0M | 2024-05-01 | $78.0M | Sequoia Capital, F-Prime, IQT +2 | 51 to 100 | 2015 |
| Xaira Therapeutics Unicorn | Xaira Therapeutics applies artificial intelligence to drug discovery and biotechnology research. | Artificial intelligence | South San Francisco, United States | Series A | $1.0B | 2024-04-23 | $1.0B | Sequoia Capital, New Enterprise Associates, Menlo Ventures +2 | 101 to 250 | 2023 |
| Comanche Biopharma | Comanche Biopharma works to make pregnancies around the world safer. | Biotech | Concord, United States | Series B | $75.0M | 2024-01-17 | $111.1M | New Enterprise Associates, Google Ventures, F-Prime +2 | 11 to 50 | 2020 |
| Burro | Burro builds autonomous mobile robots that work safely alongside people in outdoor agricultural and industrial settings. | Hardware | Philadelphia, United States | Series B | $24.0M | 2024-01-09 | $36.6M | Everywhere Ventures, Village Capital, F-Prime +2 | 51 to 100 | 2017 |
| Nvelop Therapeutics | Nvelop Therapeutics develops genetic medicines for patients with severe genetic diseases. | Biotech | Cambridge, United States | Seed | $100.0M | 2023-09-20 | $100.0M | F-Prime, Atlas Venture, 5AM Ventures +1 | 51 to 100 | 2022 |
| Better Life Partners | Better Life Partners provides medical and behavioral healthcare to help people recover from addiction. | Health care | Manchester, United States | Series B | $26.5M | 2023-08-29 | $38.2M | Alumni Ventures, F-Prime, .406 Ventures +2 | 51 to 100 | 2018 |
| Tradier | Tradier provides developers, platform providers and investors with a trading platform and real-time APIs. | Fintech | Charlotte, United States | Series B | $24.6M | 2023-04-13 | $30.7M | Eight Roads Ventures, F-Prime, Peak 6 +2 | 51 to 100 | 2012 |
| Hone | Hone provides management training to help high-growth companies develop their leaders. | Education | Encinitas, United States | Series B | $30.0M | 2022-08-19 | $52.4M | Bossa Invest, Gaingels, F-Prime +2 | 51 to 100 | 2018 |
| Logixboard | Logixboard provides white-labeled customer experience software that helps logistics providers increase sales and retain customers. | Software | Seattle, United States | Series B | $32.0M | 2022-01-26 | $50.8M | Techstars, Insight Partners, Liquid 2 Ventures +2 | 51 to 100 | 2016 |
| Parrot Software | Parrot Software helps restaurants move their systems to its own platform with modern tools like automated sales. | Software | Monterrey, Mexico | Series A | $9.5M | 2022-01-10 | Y Combinator, Alumni Ventures, F-Prime +1 | 51 to 100 | 2020 | |
| Notable | Notable provides an AI platform for healthcare operations. | Artificial intelligence | San Mateo, United States | Series B | $100.0M | 2021-11-03 | $119.2M | Greylock, 8VC, F-Prime +2 | 251 to 500 | 2017 |
| Guros | Guros enables companies to generate revenue from insurance offerings while boosting retention of their core business. | Fintech | Mexico City, Mexico | Seed | $5.8M | 2021-07-28 | F-Prime, Clocktower Technology Ventures, Magma Partners +2 | 51 to 100 | 2013 | |
| Castor | Castor provides a cloud-based clinical data platform that organizes and manages clinical trial processes. | Health care | Amsterdam, The Netherlands | Series B | $45.0M | 2021-07-14 | $64.4M | Eight Roads Ventures, F-Prime, Two Sigma Ventures +1 | 251 to 500 | 2012 |
| Orient Speech Therapy Center | Orient Speech Therapy Center operates Chinese speech and language therapy services. | Education | Shenzhen, China | Series C | $60.0M | 2021-06-25 | Eight Roads Ventures, Northern Light Venture Capital, F-Prime +2 | 1,001 to 5,000 | 2007 |
Table 1. F-Prime portfolio companies: the 30 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 75.
Largest rounds
Last 12 months| # | Company | What they do | Sector | Location | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | T-Therapeutics | T-Therapeutics develops T cell receptor therapies, spun off from the University of Cambridge. | Biotech | Cambridge, United Kingdom | Series B | $133.0M | 2026-11-05 | $224.6M | F-Prime, Sofinnova Partners, Digitalis Ventures +2 | 51 to 100 | 2022 |
| 2 | Albert Invent | Albert Invent builds an AI platform that supports chemistry research and development for scientific and industrial users. | Artificial intelligence | Oakland, United States | Series B | $55.0M | 2026-10-13 | $105.0M | Index Ventures, F-Prime, Homebrew | 101 to 250 | 2022 |
| 3 | Nocion Therapeutics | Nocion Therapeutics develops pharmaceuticals to treat conditions arising from neurogenic inflammation. | Biotech | Cambridge, United States | Series B | $23.0M | 2026-01-07 | $134.0M | Canaan Partners, F-Prime, OUP (Osage University Partners) +2 | 11 to 50 | 2017 |
| 4 | Immuneel Therapeutics | Immuneel Therapeutics develops cell and gene therapies to treat cancer. | Health care | Bangalore, India | Series B | $10.5M | 2026-06-08 | $37.6M | Eight Roads Ventures, F-Prime, True North | 51 to 100 | 2018 |
Table 2. F-Prime portfolio companies: the 4 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | Eight Roads Ventures | Venture capital firm | London, United Kingdom | 25 | 33% | 1 | Immuneel Therapeutics |
| 2 | Y Combinator | Startup accelerator | Mountain View, United States | 10 | 13% | ||
| 3 | Sequoia Capital | Venture capital firm | Menlo Park, United States | 5 | 7% | ||
| 4 | ARCH Venture Partners | Venture capital firm | Chicago, United States | 5 | 7% | ||
| 5 | Gaingels | Syndicate | Burlington, United States | 4 | 5% | ||
| 6 | Techstars | Startup accelerator | New York, United States | 4 | 5% | ||
| 7 | Bessemer Venture Partners | Venture capital firm | San Francisco, United States | 3 | 4% | ||
| 8 | Maverick Ventures | Venture capital firm | San Francisco, United States | 3 | 4% | ||
| 9 | Alumni Ventures | Angel group | Manchester, United States | 3 | 4% | ||
| 10 | Google Ventures | Corporate venture arm | San Francisco, United States | 3 | 4% | ||
| 11 | Qiming Venture Partners | Venture capital firm | Shanghai, China | 2 | 3% | ||
| 12 | Andera Partners | Private equity firm | Paris, France | 2 | 3% | ||
| 13 | FirstMark | Venture capital firm | New York, United States | 2 | 3% | ||
| 14 | Goldman Sachs | Investment bank | New York, United States | 2 | 3% | ||
| 15 | Insight Partners | Private equity firm | New York, United States | 2 | 3% |
Table 3. F-Prime portfolio companies: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Software | 51 | 68% | $5.1B |
| Health care | 31 | 41% | $5.4B |
| Fintech | 17 | 23% | $640.7M |
| Biotech | 16 | 21% | $3.7B |
| Artificial intelligence | 10 | 13% | $2.3B |
| Hardware | 6 | 8% | $354.9M |
| Cybersecurity | 5 | 7% | $315.1M |
| Education | 4 | 5% | $322.9M |
| Commerce | 1 | 1% | $10.9M |
Table 4. F-Prime portfolio companies by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
Table 5. F-Prime portfolio companies by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Countries
| Countries | Companies | Share |
|---|---|---|
| United States | 59 | 79% |
| China | 4 | 5% |
| Mexico | 3 | 4% |
| United Kingdom | 2 | 3% |
| India | 2 | 3% |
| Switzerland | 2 | 3% |
| Chile | 1 | 1% |
| Bermuda | 1 | 1% |
| The Netherlands | 1 | 1% |
Table 6. F-Prime portfolio companies by headquarters country. Source: FundingWatcher. Data as of 16 November 2026.
Cities
| Cities | Companies | Share |
|---|---|---|
| San Francisco | 8 | 11% |
| Boston | 8 | 11% |
| New York | 7 | 9% |
| Cambridge | 6 | 8% |
| Seattle | 2 | 3% |
| South San Francisco | 2 | 3% |
| Bangalore | 2 | 3% |
| Los Angeles | 2 | 3% |
| Basel | 2 | 3% |
| Salt Lake City | 2 | 3% |
| Mexico City | 2 | 3% |
| Oakland | 1 | 1% |
Table 7. F-Prime portfolio companies by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| November 2026 | 1 | 25% | $133.0M |
| October 2026 | 1 | 25% | $55.0M |
| June 2026 | 1 | 25% | $10.5M |
| January 2026 | 1 | 25% | $23.0M |
Table 8. F-Prime portfolio companies: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 4 | 5% | $221.5M |
| 2025 | 10 | 13% | $857.0M |
| 2024 | 16 | 21% | $2.1B |
| 2023 | 4 | 5% | $260.9M |
| 2022 | 9 | 12% | $168.3M |
| 2021 | 10 | 13% | $341.7M |
Table 9. F-Prime portfolio companies by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2023 or later | 5 | 7% |
| 2020 to 2022 | 15 | 20% |
| 2015 to 2019 | 23 | 31% |
| 2010 to 2014 | 27 | 36% |
| Before 2010 | 5 | 7% |
Table 10. F-Prime portfolio companies by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 7 | 9% |
| 11 to 50 | 19 | 25% |
| 51 to 100 | 24 | 32% |
| 101 to 250 | 14 | 19% |
| 251 to 500 | 6 | 8% |
| 501 to 1,000 | 3 | 4% |
| 1,001 to 5,000 | 2 | 3% |
Table 11. F-Prime portfolio companies by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when F-Prime is recorded as one of its investors. On 16 November 2026 that is 75 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 30 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 75 rows: 3 have no round amount, 0 no city and 3 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many F-Prime portfolio companies are on the list?
- 75, in the file dated 16 November 2026. 4 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 75 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.